Avalon, Qi enter definitive agreement to co-develop cannabis breathalyzer

Avalon (ALBT) GloboCare announced that it entered into a definitive agreement with Qi Diagnostics, a nanosensor-based diagnostic technologies company, to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer. Through this strategic collaboration, Avalon, Q&A Distribution, a subsidiary of Avalon, and Qi Diagnostics will jointly design, validate, and develop a prototype for the cannabis breathalyzer device, which is aimed at supporting real-time detection of potential cannabis-impaired driving and enhancing public safety. “This partnership represents an exciting step in Avalon’s mission to deliver innovative diagnostic solutions that directly impact public health and safety,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “By combining Avalon’s regulatory expertise with Qi Diagnostics’ VOC nanosensor technology, we aim to provide a real-time, non-invasive cannabis detection solution that can support law enforcement and workplace safety.”